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Bureaucracy stifles medical research in Britain: a
tale of three trials
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Abstract
Background: Recent developments aiming to standardise and streamline processes of gaining the necessary
approvals to carry out research in the National Health Service (NHS) in the United Kingdom (UK), have resulted in
lengthy and costly delays. The national UK governmental Department of Health’s Research Governance Framework
(RGF) for Health and Social Care requires that appropriate checks be conducted before research involving human
participants, their organs, tissues or data can commence in the NHS. As a result, medical research has been
subjected to increased regulation and governance, with the requirement for approvals from numerous regulatory
and monitoring bodies. In addition, the processes and outcomes of the attribution of costs in NHS research have
caused additional difficulties for researchers. The purpose of this paper is to illustrate, through three trial case
studies, the difficulties encountered during the set-up and recruitment phases of these trials, related to gaining the
necessary ethical and governance approvals and applying for NHS costs to undertake and deliver the research.
Methods: Empirical evidence about delays and difficulties related to regulation and governance of medical
research was gathered during the period 2009–2010 from three UK randomised controlled trials with sites in
England, Wales and Scotland (1. SAFER 2- an emergency care based trial of a protocol for paramedics to refer
patients directly to community based falls services; 2. COnStRUCT- a trial of two drugs for acute ulcerative colitis;
and 3. Family Links - a trial of a public health intervention, a 10 week community based parenting programme).
Findings and recommendations were reported in response to a call for evidence from The Academy of Medical
Sciences regarding difficulties encountered in conducting medical research arising from R&D governance and
regulation, to inform national policy.
Results: Difficulties and delays in navigating and gaining the appropriate approvals and NHS costs required to
undertake the research were encountered in all three trials, at various points in the bureaucratic processes of ethical
and research and information governance approvals. Conduct of each of the three trials was delayed by at least
12 months, with costs increasing by 30 – 40%.
Conclusions: Whilst the three trials encountered a variety of challenges, there were common issues. The processes
for gaining approvals were overly complex and differed between sites and UK countries; guidance about processes
was unclear; and information regarding how to define and claim NHS costs for undertaking the research was
inconsistent. The competitive advantage of a publicly funded, open access health system for undertaking health
services research and clinical trials within the UK has been outweighed in recent years by stifling bureaucratic
structures and processes for governance of research. The recommendations of the Academy of Medical Sciences
are welcomed, and the effects of their implementation are awaited with interest.
Trial Registration numbers: SAFER 2: ISRCTN 60481756; COnStRUCT: ISRCTN22663589;
Family Links: ISRCTN 13929732
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Background
McKinsey [1] and Cooksey [2] advocated and achieved
substantial investment in the infrastructure for medical
research within the United Kingdom (UK). They
applauded the excellent opportunities for world-class
medical research within the National Health Service
(NHS), and recognised widespread failure to exploit
these opportunities through cumbersome regulations
and processes. The UK Clinical Research Collaboration
(UKCRC) aimed to establish a national infrastructure for
clinical research, with the goal of “creating a clinical re-
search environment that will improve national health,
increase national wealth, and enrich world knowledge”.
A key element of the UKCRC is a national network of
research networks – topic specific (e.g. Mental Health
Research Network) and generic (Comprehensive Local
Research Networks – CLRNs), to encourage participa-
tion in high quality clinical studies, managed through
the National Institute for Health Research (NIHR) “port-
folio” and to provide a coordinated and efficient infra-
structure of research personnel and facilities to support
patient recruitment to these studies [3].
However difficulties were still encountered following the
efforts to streamline and invigorate these processes [4,5].
Research within the UK health services has seen a shift
in recent years from being a largely unregulated activity,
carried out independently of external controls to becom-
ing a formalised, regulated and institutionalised process
[6]. This has centred largely around the publication in
2005 of the Department of Health’s Research Govern-
ance Framework (RGF) for Health and Social Care that
requires, in line with European Union and wider inter-
national standards, that appropriate checks be carried
out before research involving human participants, their
organs, tissues or data can commence [7]. Researchers
within the UK have to seek approvals from Research
Ethics Committees (RECs) and local Research and De-
velopment (R&D) committees prior to starting their re-
search in the NHS.
Following trial set-up and agreement of funding, local
agreement is sought in principle with the Comprehen-
sive Local Research Networks (CLRN) or equivalent in
order to steer the process of gaining local governance
approvals (see Figure 1). The governance approvals
process then formally begins with the submission of a
nationally standardised on-line application form, cur-
rently administered through the Integrated Research Ap-
plication System (IRAS) which was launched in January
2008 (see Figure 2). This begins with the process of gain-
ing global Research Ethics Committee (REC) approvals.
If required, applications are also made at this point,
through IRAS, to the Medicines and Healthcare pro-
ducts Regulatory Agency (MHRA) or other appropriate
committees (for example if access to patient data is
required). Following REC approvals, local level NHS Re-
search and Development (R&D) approvals are sought.
‘Coordinated’ systems for gaining R&D approvals have
been implemented to facilitate this process in England, and
to some extent in Scotland and Wales. In England the
NIHR Coordinated System for gaining NHS Permission
(CSP) is a system designed to support the application and
approvals process for NHS R&D approval for publicly
funded peer-reviewed research. Topic-specific networks or
CLRNs steer this process, with a lead assigned to each case,
dependent on the location of the study Chief Investigator.
In Wales, at the time of this study, individual Trust R&D
applications had to be made with the support of The Na-
tional Institute for Social Care and Health Research Cli-
nical Research Centre (NISCHR CRC) for portfolio studies
in secondary care, with a separate process for studies in
primary care (Streamlined NHS Permissions Approach to
Research- Wales (SPARC). For multi-centre research in
Scotland, the NHS Research Scotland (NRS) Permissions
Coordinating Centre (CC) coordinates the process of
obtaining permissions from Scottish Health Boards.
In many instances NHS partners incur costs related to
administration of the research processes of studies (ser-
vice support costs) and/or to increase the throughput of
patients or the level of care given to them (excess treat-
ment costs). These costs cannot be included in the ap-
plication to NIHR research funding bodies but are
recoverable, in principle, through applications to Pri-
mary Care Trusts (PCTs) and CLRNs in England and
their equivalents in Wales and Scotland.
Recent publications in both the medical and mainstream
press have further highlighted difficulties and barriers to
undertaking medical research [8-10]. In response to these
issues, the Academy of Medical Sciences recently called
for evidence regarding difficulties encountered in conduct-
ing medical research arising from R&D governance and
regulation [11,12].
We supplied evidence in response to this call, and
summarise our recent experience related to the set up
and delivery of three NIHR portfolio trials here.
Methods
We gathered empirical evidence regarding the govern-
ance and regulatory processes (including ethical ap-
proval, research and information governance, MHRA
approvals and applications for support funding in the
form of excess treatment and service support costs)
from the set-up and recruitment phases of three rando-
mised controlled trials, each of which was registered as a
portfolio study, during the period 2009–2011. The three
trials were being carried out in sites across England,
Wales and Scotland: 1. SAFER 2- an emergency care
based trial of a protocol for paramedics to refer patients dir-
ectly to community based falls services; 2. COnStRUCT- a
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trial of two drugs for acute ulcerative colitis; and 3. Family
Links - a trial of a public health intervention, a ten week
community based parenting programme (see Table 1).
We gathered data from research protocols, project ma-
nagement documents and correspondence with project
funders and regulatory bodies, and summarised our find-
ings into common themes. We mapped the time taken to
carry out all the regulatory processes and obtain the neces-
sary governance approvals in order to set-up the three
trials against the original project milestone charts. We con-
sulted with the trial managers and principal investigators
for each of the three trials and gained original documenta-
tion and letters which specified the submission and ap-
proval dates for all the governance and regulatory
processes. Where further clarification was necessary, ad-
ditional information was sought from minutes of steering
or project team meetings. Where delays were experienced,
the resource implications of the protracted application pro-
cesses were extracted from extension applications to the
project funders.
Findings and recommendations from the three trials were
reported in to the call for evidence from The Academy of
Medical Sciences regarding difficulties encountered in
conducting medical research arising from R&D govern-
ance and regulation, to inform national policy.
Results
Research Ethics Committee (REC) approvals
We experienced problems gaining a positive ethical deci-
sion at the outset of the SAFER 2 trial because, in this
cluster randomised controlled trial, we had proposed an
opt-out consent process to access medical records in order
to follow up patient outcomes. This mirrored another trial
in the same population (older people for whom a 999 call
Figure 1 Application process for gaining approvals in the UK prior to beginning a trial.
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had been made for a fall), that was underway and that had
been approved by the same REC. Consent is acknowl-
edged to be problematic [13,14] in research in the emer-
gency care setting.
The absence of clear guidelines in this field resulted in
diversion of the application to the National Information
Governance Board for health and social care (NIGB).
The REC and the NIGB offered conflicting opinions
regarding what consent processes should be employed in
the trial. Illustrating the confused boundaries between
regulatory bodies, information governance issues were
raised by the REC and ethical issues were raised by the
NIGB with no clear path to resolution. This resulted in a
substantial use of resources (researcher time, as well as
the time of both panels) and delays. A positive ethical
opinion for the trial, with substantially amended consent
processes, was given one year after our initial application.
The COnStRUCT and Family Links trials experienced
no major problems or delays in gaining REC approval.
Research and development (R&D) approvals
Once ethical approval had been gained for the SAFER 2
trial, we sought R&D permissions from 26 NHS partners
within five CLRNs (or Welsh equivalent) across three
participating ambulance service sites. The process of
R&D governance was further complicated by the fact
that the trial included sites in England and Wales which
had different processes for gaining approvals. The CSP
was in place in England, which streamlined the process
to a certain degree, however we still experienced varying
levels of feedback and communication with designated
CLRNs as well as different processes at individual site
level for approval of studies. In Wales, R&D approval at
local level was still dependent on agreement at local
committees, many of whom required completion of their
own additional R&D application forms and processes, in
addition to the generic IRAS form.
The COnStRUCT trial included over 40 trial sites
based in England, Wales and Scotland for which re-
search governance approval was required. The process
of gaining these R&D approvals was delayed while we
sought agreement to transfer from previously completed
National Research Ethics Service (NRES) documentation
to the IRAS system. This was an important step in
allowing the study to progress through the then recently
introduced CSP, which was considered vital given the
Figure 2 Details of application processes required for the 3 trials.
Snooks et al. BMC Medical Research Methodology 2012, 12:122 Page 4 of 9
http://www.biomedcentral.com/1471-2288/12/122
number of sites that would be involved. The CSP process
began in May 2009. A further necessary step in the
process was approval from the Medicines and Healthcare
products Regulatory Agency (MHRA), which took longer
than expected due to technical issues and the initial loss
of the application by the MHRA. Despite claims that the
CSP would streamline administration, in practice it proved
very complex. There was no coordinated Welsh process in
place at the time. The sheer volume of sites involved led
to technical difficulties, with IRAS unable to cope with the
high number of potential sites. After 12 months fewer
than half of the participating NHS partner sites had given
R&D approval for this trial.
The Family Links trial was simpler in terms of geog-
raphy, as it took place in four sites in Wales, but more
complex from the point of view of recruitment. As the
intervention was a group-based programme run in
school term time, there were only three opportunities to
recruit each year. Following REC approval, we sought
R&D permissions from each partner NHS site in order
to recruit families through community based children’s
centres, with support from NHS based research support
services. Several local R&D committees highlighted ethi-
cal issues, seeming to work in isolation and causing
delays to the start of the trial. When the initial recruit-
ment strategy, through the children’s centres, failed to
meet projected targets we decided to extend recruitment
by involving general practices in the four study areas.
We made an application to SPARC to approach general
practices. The application coincided with local NHS
reconfigurations and the swine flu pandemic which were
both cited as being responsible for delays. Approval to
contact general practices in two of these areas was fi-
nally gained six months after our application. Given the
lead time on setting up recruitment through this route,
it was already too late to use this approach and the op-
portunity to recruit from general practice thus passed.
Additional efforts and new strategies for boosting recruit-
ment through the children’s centres were successful, but
the recruitment period had been lengthened considerably.
Attribution and reimbursement of costs
Completion of the process of gaining R&D approvals
was further delayed in the SAFER2 trial by the failure of
the various parties involved - the CLRNs, participating
NHS sites and the research funder - to agree on who
should pay for what. This was compounded by the issue
and subsequent withdrawal of new national guidance on
cost attribution in research (ReSeT) during this process.
Protracted discussions between the research team, the lead
CLRN and the Department of Health eventually helped to
agree cost attributions, but still discussions remained at
local level regarding the level of these costs and formal
agreement of their reimbursement to NHS partners, neces-
sary before these organisations would complete the sign up
processes. The retrieval of these costs also presented a
challenge due to the different routes and application pro-
cesses that were in place in England and Wales.
In the COnStRUCT trial local NHS partner approvals were
needed to pay for the trial drugs, which in some sites were
delayed, and in others refused altogether. Local discussions
took place and business cases were submitted to NHS part-
ner sites. The outcome has been unsuccessful at several part-
ner sites in spite of the fact that one of the drugs used has
been recommended by NICE for ‘use in research’ and as an
NIHR study, the NHS is obliged to meet the treatment costs.
Attribution of costs was not an issue for the Family
Links Trial which took place within a local authority and
was not covered by existing agreements between re-
search funders and the NHS.
Table 1 Overview of the three NIHR portfolio studies included in this paper
SAFER 2 COnStRUCT Family Links
Research Design Cluster randomised controlled trial Individually randomised controlled trial Individually randomised controlled trial
Health Technology
(Intervention) being
assessed
Treatment protocol and care pathway Comparison of two drugs for the
treatment of acute severe Ulcerative Colitis
10 week group based parenting
programme (2 hours per week)
Population Older people (aged >= 65) who have
suffered a fall and for whom a call has
been made to the emergency
ambulance service
Age 18 and over suffering with
acute severe Ulcerative Colitis
Parents with children aged 2 - 4
Sites South Wales, Nottingham,
North East London
Greater than 40 secondary care
sites throughout the UK
4 centres in South Wales
Sample size 6336 480 288
Funding body NIHR Health Technology
Assessment Programme
NIHR Health Technology
Assessment Programme
Consortium of Local Authorities with
Welsh Assembly Government
Initial funding
awarded
£1.2 million £1.69 million £350,000
Initial timescale 2009 - 2012 2008-2012 2008 - 2011
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Impact on the three trials
The delays to each trial are shown in Figure 3. In the
SAFER 2 trial, one minor amendment took in excess of
4 months to gain approval (with some local R&D approvals
still outstanding). The amendment was the addition of an
attractive front cover to the existing approved question-
naire in order to improve response rates. To be able to use
the front sheet we had to gain approval from our trial task
and finish group, the ethics committee who originally
approved the trial, the sponsor of the trial and each
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Figure 3 Timeless for the SAFER 2, COnStRUCT, and Family Links Trials, showing delays attribute to R&D governance and regulation
processes.
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individual R&D committee. The time spent on the tasks
associated with gaining approval approximated to around
3 days of work for a senior researcher.
For SAFER 2, delays in gaining approvals and the laby-
rinthine negotiations regarding attribution of costs
delayed the project start by 12 months and increased ex-
penditure by 40%, from £1.2 million to approximately
£1.7 million. We were granted additional funding for all
the extension costs from the NIHR HTA. The NIHR
requested that the trial gain all the necessary approvals
prior to further payments being made. However, we
pleaded special circumstances on SAFER 2 and the
NIHR agreed to release payments.
The protracted process of gaining approvals in
addition to unresolved discussions in relation to who
should pay for the expensive drugs, compounded by
slower than anticipated patient recruitment on COn-
StRUCT will delay reporting by at least 24 months. A
delay of at least one year can be attributed to research
governance, albeit staggered across sites. We have re-
cently applied to the NIHR HTA for a 2 year extension
and are awaiting the outcome. If granted the result will
be an increase in expenditure of 50%, from £1.6 million
to approximately £2.4 million.
The funders of the Family Links trial, have extended
the trial period twice and increased the budget by more
than 75% in order to achieve the target sample size with-
out recruiting from general practices. Results were
delayed by one year , with an increase in trial costs from
£0.35 million to £0.82 million. All additional extension
funding was received from the original funder.
Discussion
While these three trials encountered different challenges,
there were common issues between them. Although for
two of the trials, gaining ethical approvals was fairly
straightforward (COnStRUCT and Family Links), for
SAFER 2 this was problematic despite the fact similar
methodology had been employed in a previous trial with
the same population of patients. Advice regarding ap-
propriate ethical practice in research in populations at
risk is arcane [15,16] and this presents RECs with diffi-
culties when reviewing such studies. The lengthy pro-
cesses of gaining consent to participate in a trial in the
emergency care setting, has recently been shown to di-
rectly contribute to increased mortality (The CRASH 2
trial [17]). It was also found that the processes for gain-
ing NHS R&D permissions were complex and differed
both between sites and the three UK countries (England,
Wales and Scotland) involved. Information about these
processes and best practice in responding was also elu-
sive. Gaining R&D permissions was especially difficult
without clarity about the financial consequences of
participation, with inconsistency regarding how to re-
claim and categorise these costs.
Our findings mirror those of other medical research-
ers. In a pragmatic study where no medical intervention
was given, the authors suggest that an additional
150 days should be added to a research study to allow
time to gain local R&D approvals [18]. This proved to be
an underestimate in each trial case study described in
this paper. Researchers of trials of medicinal products
have also experienced delays [19]. Even since the appa-
rent ‘streamlining’ of the governance processes, research-
ers have still experienced difficulties [20]. In collating the
evidence resulting from its call regarding delays and diffi-
culties related to regulation and governance of medical re-
search, the Academy of Medical Sciences report highlights
the difficulties encountered and points to significant
delays in obtaining necessary approvals [21]. The report
highlights that in some population groups such as Cancer
patients, these delays could extend much further with a
figure of greater than 600 days given [21].
Attributing costs to our trials was also difficult. Des-
pite the fact that NHS partner sites have ways to reclaim
the costs of undertaking research, advice regarding how
to interpret the cost allocation guidance (‘Attributing
Revenue Costs of non-commercial research in the NHS
(ARCO)’ [22]) was inconsistent. Warlow similarly high-
lighted that the regulations governing who pays for what
in research in the NHS do not work [23]. Having to
navigate through these governance processes has been
met with significant bureaucracy, delay and costs
[19,21,23-25].
To conduct medical research in the UK in the face of
interminable delays and spiralling costs is decreasingly
attractive to researchers, clinicians and funders. Profes-
sor Sir Michael Rawlins, in summing up the evidence of
the Academy of Medical Sciences report reiterated this:
“We have found unequivocal evidence that the health re-
search in this country is being jeopardised by a regula-
tory and governance framework that has become
unnecessarily complex and burdensome. Further, we
received no evidence that this increased regulatory and
governance burden has led to enhanced safeguards for
participants in research” [21]. The report proposed a
number of recommendations: to create a new Health Re-
search Agency to rationalise the regulation and govern-
ance of all health research; to have a single system for
ethics approvals; to improve the UK environment for
clinical trials; to provide better access to patient data for
approved research; and to embed a culture that values
UK research [21].
We fully endorse the findings of the Academy of Me-
dical Sciences report and while conscious that the issues
are complex, on the basis of our experiences in these
three trials, we recommend that the research governance
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systems could be improved in a number of ways. There
are some populations where normal consent procedures
are not possible. Research in emergency care or invol-
ving elderly patients are two such examples. The Na-
tional Research Ethics Service should issue clear
guidance to RECs on acceptable recruitment and con-
sent procedures for these populations at risk, in order to
avoid protracted discussions regarding the most appro-
priate procedures. Many NHS R&D departments still
work independently and undertake their own processes
of review, despite approvals already having been
approved elsewhere. The NIHR should issue standard
operating procedures for local NHS R&D departments
to ensure practises are standardised. Whilst undertaking
these trials we encountered difficulties regarding the ap-
propriate attribution of costs, based on varying advice
received. Even when attribution of costs had been
agreed, local level agreement and sign-up to reimburse-
ment was difficult. The guidance for attribution of costs
for undertaking research within the NHS needs to be
further clarified, with one body taking sole responsibility
for all costs (research, excess treatment and service sup-
port costs) associated with undertaking research.
Conclusions
Following the publication of the Research Governance
Framework for Health and Social Care, medical
researchers have been subjected to numerous additional
regulatory and application processes. Although designed
to safeguard the participants and researchers involved,
introduction of these regulatory processes has often
resulted in significant time delays and inflated research
costs. Further streamlining and standardisation of these
processes in needed to ensure that high-quality research
can continue in the UK.
The competitive advantage of a publicly funded, open
access health system for undertaking health services re-
search and clinical trials has been outweighed in recent
years by stifling bureaucratic structures and processes
for governance of research in the UK. New guidance
from the Academy of Medical Sciences and plans set out
in this year’s budget for a Health Research Regulatory
Agency to streamline the regulations on clinical trials,
and so make them cheaper and easier to run [26],
present another opportunity to tidy up structures and
processes. As researchers, we await with interest the
effects in practice on the time and cost of set up and de-
livery of publicly funded NHS based research in the UK.
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